Lonza Engine™ Equipment Portfolio Launched for Small Molecule Formulation and Dosage Forms
Basel (CH), 10 June 2019 – Today, Lonza announced the launch of the Lonza Engine™ comprehensive, technical service platform which includes the equipment portfolio of the legacy Capsugel and Micromacinazione companies. The new offering is designed to address the needs of customers throughout the entire small molecule drug development process.
The Lonza Engine™ equipment portfolio has been created to support bioavailability enhancement, encapsulation and early-phase clinical development technologies. It offers state-of-the-art machines including micronization, capsule filling and sealing, and powder micro-dosing equipment.
“Lonza offers a powerful range of world-class industrial equipment that has earned the trust of our customers, who can rely on our proven technology: we know it works because we use it first,” says Christian Dowdeswell, VP and Head of BU Dosage Forms & Delivery Systems, Lonza Pharma & Biotech. “Above all, our equipment is backed by a global network of business and technical support services designed to help customers to get the most out of their production process.” The Xcelodose™ powder micro-dosing system within the portfolio provides highly consistent dose accuracy by precise filling of capsules without excipients or bulking agents. The capsule filling and sealing (CFS) equipment provides support for lipid-based formulations to improve the bioavailability of poorly soluble compounds. In addition, thanks to the micronization equipment, the desired particle size distribution of the drug substance can be reached in order to improve the drug product performance.
The Lonza Engine™ platform is backed by Lonza’s outstanding technical service that includes basic technical training, advanced seminars, and components ordering support.
The addition of the Lonza Engine™ offering broadens Lonza’s already comprehensive equipment portfolio for capsule filling, now providing solutions for the entire drug product development process.
“The new equipment portfolio complements our offerings for the pharma and consumer health and nutrition industries and supports our goal to serve markets along the Healthcare Continuum®,” adds Fabio Invernizzi, VP Global Sales, Capsule Delivery Solutions, Lonza Pharma & Biotech.
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.
Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com.
Lonza Contact Details
Dirk Oehlers, Head Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540
Dr Sanna Fowler
Head of Public Relations
Lonza Pharma & Biotech
Tel +41 61 316 8929
Head of Global Marketing
Capsule Delivery Solutions
Tel +32 3 890 05 11
Constance Ward, Head
Lonza Group Ltd
Tel +41 61 316 8840